Top Markets
#1 The Bitcoin Bull The Bitcoin Bull +29.50%
#2 Mubarak Mubarak +29.14%
#3 Dash Dash +22.15%
#4 Official Trump Official Trump +21.81%
#5 EXOD EXOD +18.93%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +17.43%
#7 Binance-Peg ZEC Binance-Peg ZEC +16.52%
#8 NEAR Intents Bridged ZEC NEAR Intents Bridged ZEC +16.37%
#9 Unit Zcash Unit Zcash +16.37%
#10 Zcash Zcash +16.37%
Coin of the day
The Bitcoin Bull The Bitcoin Bull
Settings
Language
ENGLISH
Currency
USD
Theme
Heat Biologics, Inc. Heat Biologics, Inc.

Heat Biologics, Inc.

HTBX
Rank in Stocks #24400
Heat Biologics, Inc. is an integrated biopharmaceutical company focused on... Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Share Price
$2.38
Last synced: 2022-05-03
Market Cap
$61.07M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Heat Biologics, Inc. (HTBX)

Category

Healthcare
P/E ratio for Heat Biologics, Inc. (HTBX)
P/E ratio as of 2026 TTM: 0
According to Heat Biologics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Heat Biologics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.